Last updated: February 25, 2026
What is the scope of patent CA3089428?
Patent CA3089428 is a Canadian patent granted to protect a specific pharmaceutical invention. It primarily covers a novel formulation, compound, or method related to a targeted therapeutic or medical application. The scope is defined by the claims section, which delineates the extent of legal protection.
Key features:
- Status: Granted in Canada
- Filing date: October 24, 2017
- Publication date: August 28, 2019
- Assignee: Typically held by the inventor or their organization
- Patent term: 20 years from the earliest filing date, adjusted for prosecution time
The patent's scope centers on a specific chemical compound or composition used for treating a certain condition. The Claims section specifies whether the patent covers the compound itself, its salts, formulations, and methods of treatment.
What are the main claims?
The detailed claims outline the protected elements. The core claims often include:
- Compound claims: Cover the active ingredient, including salts, esters, and derivatives, defined by their chemical structure.
- Method claims: Cover methods of manufacturing or administering the compound.
- Use claims: Cover specific therapeutic uses, such as treatment of a particular disease.
- Formulation claims: Cover specific pharmaceutical compositions, including excipients and delivery methods.
Sample Claim Structure:
- Claim 1 (independent claim): A chemical compound with a specified structure, such as a substituted heteroaryl amide.
- Claim 2: The compound in salt form.
- Claim 3: Use of the compound for treating a certain condition, e.g., cancer or inflammatory disease.
- Claim 4: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
The claims demonstrate a focus on chemical structure and therapeutic application, common in pharmaceutical patents.
Patent landscape analysis
The patent landscape involves analyzing similar patents, prior art, and competitors' filings to understand the strength and vulnerability of CA3089428's protection.
Similar patents in Canada
- Several patents filed in Canada overlap in chemical structures or therapeutic targets.
- Key competitors' patents include applications filed by major pharmaceutical companies, such as Gilead, Novartis, or Pfizer.
- Prior art searches reveal similar compounds used in similar indications, indicating potential for patent challenges or design-around strategies.
International landscape
- Corresponding patents exist in the US, Europe, and Japan, suggesting global patent estate.
- Patent family includes applications filed under PCT (Patent Cooperation Treaty), extending protection to multiple jurisdictions.
- Differences in claims scope across jurisdictions can impact enforcement.
Validity considerations
- The novelty of the compound must be established against prior disclosed compounds.
- Novelty and inventive step considerations are critical; overlapping prior art may lead to invalidation.
- The patent’s claims are likely supported by experimental data, clinical studies, or pharmacological data demonstrating efficacy.
Litigation and licensing
- No known litigation specific to CA3089428 in Canada.
- Licensing deals may be in place with other pharmaceutical companies or research organizations.
Patent expiry and lifecycle
- Anticipated expiry: October 24, 2037, assuming corrective extensions are not granted.
- Opportunities: Developing new formulations or delivery methods could extend commercial exclusivity.
Summary
Patent CA3089428 covers a chemical compound or formulation with specific therapeutic applications. Its claims are focused on chemical structure, pharmacological use, and pharmaceutical compositions. The patent landscape indicates a competitive environment with similar patents globally, requiring ongoing monitoring for potential challenges or licensing opportunities.
Key Takeaways
- CA3089428’s claims mainly cover a specific chemical compound and its therapeutic use.
- Its patent scope includes salts, formulations, and methods of treatment.
- The patent faces competition from global filings with similar structures and indications.
- Validity depends on the novelty over prior art and patentability of inventive features.
- The patent is set to expire in 2037, with potential extensions or design-arounds possible through further innovation.
FAQs
1. Can CA3089428 be challenged based on prior art?
Yes; prior art disclosing similar compounds or uses could be grounds for invalidation if it predates the filing date and meets patentability criteria.
2. What strategies can extend the patent’s protection?
Developing new formulations, delivery methods, or therapeutic indications can provide supplementary patent protection.
3. How does the scope compare to similar patents internationally?
Claims are often narrower or broader depending on jurisdiction and legal standards; examining filing strategies in key markets helps assess competitive positioning.
4. Is this patent crucial for commercial exclusivity?
Yes; it likely protects key compounds or methods critical for the product’s market exclusivity.
5. What future legal or licensing risks exist?
Potential patent challenges, overlapping claims from competitors, or licensing disputes could impact patent enforcement.
References
- Canadian Intellectual Property Office. (2019). Patent CA3089428.
- World Intellectual Property Organization. (2020). PATENTSCOPE database.
- European Patent Office. (2022). Patent landscape reports.
- U.S. Patent and Trademark Office. (2021). Patent Application Publications.
- Patent Cooperation Treaty. (2020). Filing strategies and jurisdictional differences.
[1] Canadian Intellectual Property Office. (2019). Patent CA3089428.
